Advanced search
Publication Cover
Modern Rheumatology Volume 17, 2007 - Issue 3
Journal homepage
123
Views
63
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

Yoshiya TanakaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, JapanCorrespondence[email protected]
,
Kazuhiko YamamotoDepartment of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo,Tokyo, Japan
,
Tsutomu TakeuchiDivision of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University,Kawagoe, Japan
,
Norihiro NishimotoLaboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University,Suita, Japan
,
Nobuyuki MiyasakaDepartment of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University,Tokyo, Japan
,
Takayuki SumidaDepartment of Clinical Immunology, University of Tsukuba,Ibaraki, Japan
,
Yoshihito ShimaLaboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University,Suita, Japan
,
Kazuki TakadaDepartment of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University,Tokyo, Japan
,
Isao MatsumotoDepartment of Clinical Immunology, University of Tsukuba,Ibaraki, Japan
,
Kazuyoshi SaitoFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan
&
Takao KoikeDepartment of Medicine II, Graduate School of Medicine, Hokkaido University,Sapporo, Japan
 show all
Pages 191-197 | Received 29 Jan 2007, Accepted 26 Feb 2007, Published online: 02 Jan 2014

Citations (63)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Yaxi Li & Tianfu Wu. (2018) Proteomic approaches for novel systemic lupus erythematosus (SLE) drug discovery. Expert Opinion on Drug Discovery 13:8, pages 765-777.
Read now
Jean L. Koff & Christopher R. Flowers. (2016) B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. Expert Review of Hematology 9:6, pages 553-561.
Read now
Yoshiya Tanaka, Tsutomu Takeuchi, Nobuyuki Miyasaka, Takayuki Sumida, Tsuneyo Mimori, Takao Koike, Kazuhiro Endo, Naomi Mashino & Kazuhiko Yamamoto. (2016) Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Modern Rheumatology 26:1, pages 80-86.
Read now
Alfredomaria Lurati, Luca Bertani, Mariagrazia Marrazza, Katia Angela Re, Daniela Bompane & Magda Scarpellini. (2012) NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab. Biologics: Targets and Therapy 6, pages 83-87.
Read now
E Wiesik-Szewczyk & M Olesinska. (2012) B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. Biologics: Targets and Therapy 6, pages 347-354.
Read now
A. Ahsan Ejaz, Abdo Asmar, Mourad M. Alsabbagh & Nasimul Ahsan. (2012) Rituximab in immunologic glomerular diseases. mAbs 4:2, pages 198-207.
Read now
Antonio La Cava. (2010) Targeting B cells with biologics in systemic lupus erythematosus. Expert Opinion on Biological Therapy 10:11, pages 1555-1561.
Read now
Matthew L Stoll & Alisa C Gotte. (2008) Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics: Targets and Therapy 2:2, pages 229-252.
Read now
Enno Schmidt & Matthias Goebeler. (2008) CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Review of Dermatology 3:3, pages 259-278.
Read now
Detlef Neumann, Thomas Tschernig & Diana Boraschi. (2007) Development of biologicals for the therapy of lupus erythematosus. Expert Review of Vaccines 6:6, pages 1001-1011.
Read now

Articles from other publishers (53)

Yoshiya Tanaka, Shingo Nakayamada, Kunihiro Yamaoka, Koichiro Ohmura & Shinsuke Yasuda. (2023) Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. Modern Rheumatology 33:1, pages 145-153.
Crossref
Gilda Sandri, Carlo Umberto Manzini & Carlo Salvarani. (2021) On- and off-label use of rituximab in rheumatic diseases. Beyond Rheumatology 3:1.
Crossref
D.A. Papachristos, S. Oon, J.G. Hanly & M. Nikpour. (2021) Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review. Seminars in Arthritis and Rheumatism 51:1, pages 49-71.
Crossref
Fabien B. Vincent, William A. Figgett & Margaret L. Hibbs. 2021. Pathogenesis of Systemic Lupus Erythematosus. Pathogenesis of Systemic Lupus Erythematosus 37 52 .
Rita Quelhas da Costa, M. Elena Aguirre-Alastuey, David A. Isenberg & Amanda M. Saracino. (2018) Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus. JAMA Dermatology 154:12, pages 1432.
Crossref
S Iwata, K Saito, S Hirata, N Ohkubo, S Nakayamada, K Nakano, K Hanami, S Kubo, I Miyagawa, M Yoshikawa, Y Miyazaki, H Yoshinari & Y Tanaka. (2018) Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus 27:5, pages 802-811.
Crossref
F. Proft, H. Schulze-Koops, M. Grunke, E. Schrezenmeier, F. Halleck, J. Henes, L. Unger, E. Schmidt, C. Fiehn, A. Jacobi, C. Iking-Konert, C. Kneitz, R. E. Schmidt, B. Bannert, R. E. Voll, R. Fischer-Betz, I. Kötter, H. P. Tony, J. Holle, M. Aringer, A. Erler, F. Behrens, G. R. Burmester & T. Dörner. (2017) Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen ErkrankungenSafety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy. Zeitschrift für Rheumatologie 77:1, pages 28-39.
Crossref
Caroline GordonMaame-Boatemaa Amissah-ArthurMary GayedSue BrownIan N. BruceDavid D’CruzBenjamin EmpsonBridget GriffithsDavid JayneMunther KhamashtaLiz LightstonePeter Norton, Yvonne Norton, Karen SchreiberDavid Isenberg. (2018) The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 57:1, pages e1-e45.
Crossref
Taku Yoshio & Hiroshi Okamoto. 2018. Neuropsychiatric Systemic Lupus Erythematosus. Neuropsychiatric Systemic Lupus Erythematosus 155 168 .
Heidi S. Schultz, Stine Louise Reedtz-Runge, B. Thomas Bäckström, Kasper Lamberth, Christian R. Pedersen & Anne M. Kvarnhammar. (2017) Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay. PLOS ONE 12:5, pages e0178544.
Crossref
Jessica Day, Vidya Limaye, Susanna Proudman, John D. Hayball & Pravin Hissaria. (2017) The utility of monitoring peripheral blood lymphocyte subsets by flow cytometric analysis in patients with rheumatological diseases treated with rituximab. Autoimmunity Reviews 16:5, pages 542-547.
Crossref
Borja Gracia-Tello, Amara Ezeonyeji & David Isenberg. (2017) The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Science & Medicine 4:1, pages e000182.
Crossref
Shingo Nakayamada & Yoshiya Tanaka. (2016) BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflammation and Regeneration 36:1.
Crossref
Mariele Gatto, Francesca Saccon, Margherita Zen, Silvano Bettio, Luca Iaccarino, Leonardo Punzi & Andrea Doria. (2016) Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. Journal of Autoimmunity 74, pages 94-105.
Crossref
N Annapureddy, H Devilliers & M Jolly. (2016) Patient-reported outcomes in lupus clinical trials with biologics. Lupus 25:10, pages 1111-1121.
Crossref
S Iwata & Y Tanaka. (2016) B-cell subsets, signaling and their roles in secretion of autoantibodies. Lupus 25:8, pages 850-856.
Crossref
Shingo Nakayamada, Shigeru Iwata & Yoshiya Tanaka. (2015) Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. International Journal of Rheumatic Diseases 18:2, pages 208-218.
Crossref
J.R. Kalden. 2015. Therapie-Handbuch Grundwerk inkl 6. Lfg.. Therapie-Handbuch Grundwerk inkl 6. Lfg. 1 10 .
Yusei Miyazaki & Masaaki Niino. (2014) Molecular targeted therapy against B cells in multiple sclerosis . Clinical and Experimental Neuroimmunology 5:s1, pages 16-27.
Crossref
Tatiana Cobo-Ibáñez, Estíbaliz Loza-Santamaría, José María Pego-Reigosa, Alejandro Olivé Marqués, Íñigo Rúa-Figueroa, Antonio Fernández-Nebro, Rafael Cáliz Cáliz, Francisco Javier López Longo & Santiago Muñoz-Fernández. (2014) Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. Seminars in Arthritis and Rheumatism 44:2, pages 175-185.
Crossref
B Duxbury, C Combescure & C Chizzolini. (2013) Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 22:14, pages 1489-1503.
Crossref
João Furtado & David A. Isenberg. (2013) Reprint of: B cell elimination in systemic lupus erythematosus. Clinical Immunology 148:3, pages 344-358.
Crossref
Kam Newman, Mohammad Bagher Owlia, Ihab El-Hemaidi & Mojtaba Akhtari. (2013) Management of immune cytopenias in patients with systemic lupus erythematosus — Old and new. Autoimmunity Reviews 12:7, pages 784-791.
Crossref
S Iwata, K Saito, M Tokunaga & Y Tanaka. (2013) Persistent memory B cell down-regulation after 6-year remission induced by rituximab therapy in patients with systemic lupus erythematosus. Lupus 22:5, pages 538-540.
Crossref
Jon W. Gregersen & David R. W. Jayne. (2012) B-cell depletion in the treatment of lupus nephritis. Nature Reviews Nephrology 8:9, pages 505-514.
Crossref
A Vossenkämper, P M K Lutalo & J Spencer. (2012) Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. Clinical and Experimental Immunology 167:1, pages 7-14.
Crossref
Yiyun Yu & Antonio La Cava. (2011) Current drugs in systemic lupus erythematosus. Drug Development Research 72:7, pages 561-572.
Crossref
Edward M. Vital, Shouvik Dass, Maya H. Buch, Karen Henshaw, Colin T. Pease, Michael F. Martin, Frederique Ponchel, Andrew C. Rawstron & Paul Emery. (2011) B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis & Rheumatism 63:10, pages 3038-3047.
Crossref
Alessandra Vultaggio, Enrico Maggi & Andrea Matucci. (2011) Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Current Opinion in Allergy & Clinical Immunology 11:3, pages 262-268.
Crossref
Stephanie Delluc, Gilles Ravot & Bernard Maillere. (2011) Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. The FASEB Journal 25:6, pages 2040-2048.
Crossref
Kazuyoshi Saito & Yoshiya Tanaka. (2011) 5. B Cell Targeting Biologics for Rheumatic Diseases.. Nihon Naika Gakkai Zasshi 100:10, pages 2991-2997.
Crossref
Arlene T Tieng, Gisele Zandman-Goddard & Elena Peeva. (2010) Targeting B cells to treat systemic lupus erythematosus. International Journal of Clinical Rheumatology 5:6, pages 627-636.
Crossref
Eleanor Murray & Martin Perry. (2010) Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clinical Rheumatology 29:7, pages 707-716.
Crossref
A. Lateef, M. Lahiri, GG Teng & S. Vasoo. (2010) Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus 19:6, pages 765-770.
Crossref
F. Perosa, M. Prete, V. Racanelli & F. Dammacco. (2010) CD20‐depleting therapy in autoimmune diseases: from basic research to the clinic. Journal of Internal Medicine 267:3, pages 260-277.
Crossref
Masaru Kato, Tatsuya Atsumi & Takao Koike. (2010) 2. Systemic Lupus Erythematosus. Nihon Naika Gakkai Zasshi 99:10, pages 2401-2406.
Crossref
Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace, Joseph C. Shanahan, Kevin M. Latinis, James C. Oates, Tammy O. Utset, Caroline Gordon, David A. Isenberg, Hsin‐Ju Hsieh, David Zhang & Paul G. Brunetta. (2009) Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis & Rheumatism 62:1, pages 222-233.
Crossref
Catarina Favas & David A. Isenberg. (2009) B-cell-depletion therapy in SLE—what are the current prospects for its acceptance?. Nature Reviews Rheumatology 5:12, pages 711-716.
Crossref
Andreea Coca & Ignacio Sanz. (2009) B cell depletion in lupus and Sjögren's syndrome: an update. Current Opinion in Rheumatology 21:5, pages 483-488.
Crossref
Styliani Ntali, Michail Tzanakakis, George Bertsias & Dimitrios T Boumpas. (2009) What’s new in clinical trials in lupus?. International Journal of Clinical Rheumatology 4:4, pages 473-485.
Crossref
M Ramos-Casals, MJ Soto, MJ Cuadrado & MA Khamashta. (2009) Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases. Lupus 18:9, pages 767-776.
Crossref
Luis Alonso Gonz?lez, Jos? Fernando Molina & Gloria Mar?a V?squez. (2009) Actualidad en el tratamiento de la nefritis l?pica proliferativa. Revista Colombiana de Reumatolog?a 16:1, pages 76-96.
Crossref
Catherine A. Heyneman. (2008) Systemic Lupus Erythematosus: A Therapeutic Update. Journal of Pharmacy Practice 22:1, pages 29-52.
Crossref
Angela Nagel, Michael Hertl & Rüdiger Eming. (2009) B-Cell-Directed Therapy for Inflammatory Skin Diseases. Journal of Investigative Dermatology 129:2, pages 289-301.
Crossref
Eliana A. G. Reis, Daniel A. Athanazio, Isabella Lima, Natália Oliveira e Silva, Jorge Clarencio S. Andrade, Ronden N. Jesus, Lúcio M. Barbosa, Mitermayer G. Reis & Mittermayer B. Santiago. (2008) NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatology International 29:4, pages 469-475.
Crossref
JM Kaplan, L Woodworth, K Smith, J Coco, A Vitsky & JM McPherson. (2008) Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-β1 in the MRL/lpr lupus mouse model. Lupus 17:9, pages 822-831.
Crossref
George Bertsias & Dimitrios T Boumpas. (2008) Update on the management of lupus nephritis: let the treatment fit the patient. Nature Clinical Practice Rheumatology 4:9, pages 464-472.
Crossref
DA Isenberg. (2008) Treating patients with lupus with B-cell depletion. Lupus 17:5, pages 400-404.
Crossref
Christopher F. Wong. (2008) Rituximab and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. JCR: Journal of Clinical Rheumatology 14:2, pages 61-64.
Crossref
T Fukushima, L Dong, T Sakai, T Sawaki, M Miki, M Tanaka, Y Masaki, Y Hirose, M Kuwana & H Umehara. (2008) Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus 17:3, pages 210-214.
Crossref
G. Guhl, B. Díaz-Ley & J. Fernández-Herrera. (2008) Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab. Actas Dermo-Sifiliográficas 99:1, pages 5-33.
Crossref
Changhai Ding, Simon Foote & Graeme Jones. (2008) B-Cell-Targeted Therapy for Systemic Lupus Erythematosus. BioDrugs 22:4, pages 239-249.
Crossref
G. Guhl, B. Díaz-Ley & J. Fernández-Herrera. (2008) Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 2: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab, and Cetuximab. Actas Dermo-Sifiliográficas (English Edition) 99:1, pages 5-33.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.